Placebo to metformin
Sponsors
Merck Sharp & Dohme LLC
Conditions
Diabetes MellitusDiabetes Mellitus, Type 2Type 2 DiabetesType 2 Diabetes Mellitus
Phase 2
Dose-Range Finding Study for MK0893 (0893-008)
TerminatedNCT00479466
Start: 2007-07-31End: 2008-05-31Updated: 2015-09-09
A Study of the Safety and Efficacy of MK-3577 in Participants With Type 2 Diabetes Mellitus (MK-3577-009)
TerminatedNCT00868790
Start: 2009-03-24End: 2010-07-13Updated: 2018-09-10
A Dose-Range Finding Study in Participants With Type 2 Diabetes (MK-3102-006)
CompletedNCT01217073
Start: 2010-10-08End: 2013-04-01Updated: 2018-09-10
Phase 3
Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083)
CompletedNCT01485614
Start: 2012-02-10End: 2019-10-09Updated: 2022-09-23
A Study to Assess the Safety and Efficacy of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control (MK-3102-011)
CompletedNCT01717313
Start: 2012-12-05End: 2015-06-19Updated: 2018-09-10
A Pooled Analysis of the Safety and Efficacy of MK-0431A and MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Therapy (Alone or in Combination With Insulin) (MK-0431A-170/MK-0431A-289)
CompletedNCT01760447
Start: 2011-12-07End: 2019-09-17Updated: 2022-09-23
A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003, VERTIS MONO)
CompletedNCT01958671
Start: 2013-10-09End: 2016-07-28Updated: 2017-09-29